Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes

Prostate cancer is the most commonly diagnosed cancer in men in the United States with 165,000 new cases diagnosed in 2018 (1). It is the second leading cause of cancer mortality in men, with almost 30,000 deaths in 2018 attributed to progressive metastatic disease.